ARCaPE Cell Lines Expressing shRNAs of Human EPLIN


Highly malignant and metastatic prostate cancer cell line.

Key Benefits

  • Prostate cancer cell line with reduced Epithelial Protein Lost In Neoplasm (EPLIN) expression.
  • Cell line exhibits morphology characteristics of malignant cell lines and increased chemoresistance, migration, and invasion.

Market Summary

Although the survival rates for prostate cancer have improved due to improvements in cancer detection and increased awareness, survival rates for metastatic prostate cancer remain quite low. To further improve prostate cancer survival rates, there is a large research focus on the mechanisms and treatment of metastatic prostate cancer.

Technical Summary

Prostate cancer is the second leading cause of cancer-related deaths in males in the United States, and the vast majority of those deaths result from metastatic cancer. Researchers at Emory have developed a cell line that could serve as a cell-based model to better understand the mechanisms underlying metastatic prostate cancer. Drs. Wu and Zhang determined that reduced expression of Epithelial Protein Lost In Neoplasm (EPLIN) causes a well-characterized prostate cancer cell line, ARCaPE, to behave more like a metastatic cancer cell line. Specifically, EPLIN-depleted ARCaPE cells have a fibroblast-like morphology, reduction in cell-cell contacts, increased migration and invasion, and increased chemoresistance. This cell line exhibits many of the properties of a metastatic cancer cell line and will be a useful tool for further studies on metastatic prostate cancer.

Developmental Stage

Cell lines have been generated and characterized.

Patent Information

Tech ID: RT006
Published: 5/28/2013